Hospital Infection Prevention And Control Market Expected To Grow with a CAGR of 8.0% from the forecast period of 2023-2030.
Hospital-acquired infections are a growing issue of preventable disease burden in respect of morbidity and mortality in all countries. In particular in developing countries, it poses an enormous negative impact on health delivery costs. The cost may be direct (the cost of medicines, bed occupation, etc.) or indirect (as patients are deprived of work). According to a WHO study: 55 hospitals of 14 countries in South-East Asia, Europe, the Eastern Mediterranean, and Western Pacific revealed that on average 8.7% of hospital patients suffer nosocomial infections. Globally, at least 1 in 4 patients in intensive care will acquire an infection during their stay in hospital. Thus stringent guidelines are being provided to prevent hospital infection and control the same. The WHO and various other regulatory bodies at the regional and national levels provide guidelines for hospital infection prevention and control. The rising prevalence of nosocomial infection and regulatory guidelines and measures are the driving factors of the global hospital infection prevention and control market.
Market experts suggest that healthcare-associated infections are a costly issue faced by many hospitals across the globe. Hospital-acquired infections are type of infections that are observed in patients during the course of receiving treatment for unrelated conditions. According to World Health Organization (WHO), infectious waste contributes in this way to the risk of nosocomial infections, putting the health of hospital personnel, and patients, at risk. Centers for Disease Control and Prevention (CDC) statistically suggested that, with approximately 300,000 occurrences each year, surgical site infections (SSIs) are the second most prevalent HAI in the United States, preceded only by urinary tract infections. At a cost of approximately $10 billion annually, this high incidence of SSIs significantly impacts the U.S Healthcare System, as well as the bottom line of individual hospitals.
Medical experts suggested that the occurrence of nosocomial infections has been observed worldwide in both developed and resource-poor countries. Infections acquired in health care settings are among the major causes of death and increased morbidity among hospitalized patients. According to European Centre for Disease Prevention and Control (ECDC), approximately 4100,000 patients are estimated to acquire a healthcare-associated infection in the EU each year. The number of deaths occurring as a direct consequence of these infections is estimated to be at least 37,000 and these infections are thought to contribute to an additional 110,000 deaths each year.
Rising incidence of hospital-acquired infections (HAIs), growth in the number of surgical procedures, growing aging population, and rising focus on the need for food sterilization and disinfection are major factors driving the growth of the hospital infection prevention & control market. However, factors such as stringent regulatory requirements and the need to comply with them may restrain the growth of this market during the forecast period 2023 - 2030.
The comparative analysis between 2023 and 2030 projects significant growth in segments such as MRSA, urinary tract infection, and surgical site infections. The key factors assisting the growth of these infections are the rising prevalence of infections, implementation of stringent guidelines associated with hospital infection prevention and control, developing healthcare infrastructure in emerging countries, and the rising number of hospitals across the world.
Infection Prevention Supplies is the largest segment globally
In 2020, the infection prevention supplies segment was observed as the largest segment in the overall hospital infection prevention and control market. The key factors assisting the market growth are growing emphasis on infection control policies within hospital premises and strengthening of government regulations for quality of healthcare services provided to patients. The increase in hospital admissions and outpatient visits drives demand for a number of infection prevention supplies and services. The protective apparel & textile market held the largest share in the infection prevention supplies market due to aggressive efforts by hospitals to reduce the risk of hospital-acquired infections in surgery and other invasive procedures.
Asia Pacific Dominates the Market
In the base 2020, North America formed the largest market for hospital infection prevention and control market due to the rising prevalence of nosocomial infection and stringent regulations followed by the hospitals, clinicians, and caregivers aligning with regulatory bodies. Asia Pacific is the fastest-growing segment with an increase in awareness of healthcare-associated infection, rising investment in health care infrastructure, technological advancement, and new protocols and programs conducted for infection prevention and control in line with WHO guidelines.
Key Players
Historical & Forecast Period
This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Hospital Infection Prevention And Control market are as follows:
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
| ATTRIBUTE | DETAILS |
|---|---|
| Research Period | 2022-2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Year | 2022 |
| Unit | USD Million |
| Segmentation | |
Infection Type
| |
Product
| |
|
Region Segment (2022-2032; US$ Million)
|
Key questions answered in this report
